Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
7.44
0.00 (0.00%)
Apr 24, 2026, 4:00 PM EDT - Market closed

Gyre Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
6796451,0441,96850629
Market Cap Growth
-6.96%-38.27%-46.93%289.25%1669.60%-79.48%
Enterprise Value
627.89628.811,0542,029510.17-17.88
Last Close Price
7.447.0612.1025.697.9513.65
PE Ratio
135.15353.00242.00-18.22265.0056.88
PS Ratio
5.835.539.8717.344.943.89
PB Ratio
6.416.0816.49-124.3211.890.70
P/TBV Ratio
7.016.8719.55-106.8514.1522.16
P/FCF Ratio
--3581.54-175.34113.2588.81-0.34
P/OCF Ratio
672.65638.29-286.8276.0047.35-0.34
EV/Sales Ratio
5.395.399.9617.884.99-2.44
EV/EBITDA Ratio
44.8145.0259.49-30.6749.580.20
EV/EBIT Ratio
54.6454.7465.19-30.1855.430.20
EV/FCF Ratio
--3493.37-176.90116.7689.630.21
Debt / Equity Ratio
0.000.000.010.010.000.01
Debt / EBITDA Ratio
0.070.070.09-0.010.06-0.03
Debt / FCF Ratio
-5.22-5.22-0.270.020.11-0.03
Net Debt / Equity Ratio
-0.49-0.49-0.402.09-0.58-1.08
Net Debt / EBITDA Ratio
-3.69-3.69-1.420.50-2.390.51
Net Debt / FCF Ratio
286.03286.034.21-1.90-4.320.53
Asset Turnover
0.800.800.871.131.460.10
Inventory Turnover
--1.810.891.57-
Quick Ratio
4.894.892.862.513.463.44
Current Ratio
5.605.603.322.854.063.63
Return on Equity (ROE)
8.21%8.21%31.86%-198.41%7.61%-150.11%
Return on Assets (ROA)
5.39%5.39%10.30%-74.19%6.01%-116.80%
Return on Invested Capital (ROIC)
8.40%8.40%15.70%-123.49%17.93%6266.95%
Return on Capital Employed (ROCE)
9.05%9.05%15.97%-79.56%16.14%-148.28%
Earnings Yield
0.74%0.28%0.41%-5.49%0.38%1.76%
FCF Yield
-0.03%-0.03%-0.57%0.88%1.13%-296.12%
Buyback Yield / Dilution
-0.87%-0.87%-55.39%13.02%-13.45%-5117.44%
Total Shareholder Return
-0.87%-0.87%-55.39%13.02%-13.45%-5117.44%
Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q